NCT05357027 2026-01-21
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
Phase 1/2 Terminated
Clinical Trials
20 trialsNCT04611126 2025-08-12
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT03610490 2025-04-17
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03267680 2025-04-13
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
University of Southern California
Phase 2 Terminated
NCT04025216 2024-01-24
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03608618 2021-09-05
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
MaxCyte, Inc.
Phase 1 Terminated
NCT02387125 2020-07-01
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Terminated
NCT01312376 2020-04-24
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00652899 2017-12-28
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00003852 2016-06-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
UNICANCER
Phase 2 Terminated
NCT01175772 2015-06-23
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT00002819 2013-04-11
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
GOG Foundation
Phase 3 Terminated
NCT00003386 2013-04-11
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Phase 2 Terminated
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT01212887 2012-02-28
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Cancer Research UK
Phase 1 Terminated